Article Sidebar

Submitted
October 21, 2024
Accepted
October 21, 2024
Published
October 21, 2024
Download
PDF
Statistic
Read Counter : 486 Download : 360

Main Article Content

Abstract

Abstract : Among chronic liver diseases, alcoholic liver disease (ALD) is the most common in the
world. The main cause of ALD is excessive alcohol consumption. The accumulation of fatty acids in
liver cells is one of the oldest and most famous alcohol-related changes that cause the development of
ALD . Although the mechanism by which excessive alcohol intake leads to fatty acid accumulation is
far-fetched and complex, one of the mechanisms by which alcohol affects fatty acids is the regulation
of the sterol regulatory element-binding protein-1 c (SREBP-1 C) which may be key to the treatment of
ALD. In this review, we present evidence supporting the key important role of the SREBP-1 C in
influencing the synthesis and accumulation of fatty acids that are a major cause of ALD, and we
suggest that there should be future studies to evaluate the modification of the SREBP-1 C as a possible
new treatment for alcoholic liver disease.

Article Details

License

Copyright (c) 2024 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. J. S. Bajaj, “Alcohol, liver disease and the gut microbiota,” Nat. Rev. Gastroenterol. Hepatol.,
  2. vol. 16, no. 4, pp. 235–246, 2019.
  3. Y. Ha, I. Jeong, and T. H. Kim, “Alcohol-related liver disease: an overview on pathophysiology,
  4. diagnosis and therapeutic perspectives,” Biomedicines, vol. 10, no. 10, p. 2530, 2022.
  5. J. D. Stanaway et al., “Global, regional, and national comparative risk assessment of 84
  6. behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries
  7. and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Stu,” Lancet, vol.
  8. , no. 10159, pp. 1923–1994, 2018.
  9. J. Manthey, K. D. Shield, M. Rylett, O. S. M. Hasan, C. Probst, and J. Rehm, “Global alcohol
  10. exposure between 1990 and 2017 and forecasts until 2030: a modelling study,” Lancet, vol. 393, no.
  11. , pp. 2493–2502, 2019.
  12. F. Zhong et al., “Complement C3 activation regulates the production of tRNA-derived fragments
  13. Gly-tRFs and promotes alcohol-induced liver injury and steatosis,” Cell Res., vol. 29, no. 7, pp. 548–
  14. , 2019.
  15. P. Sharma and A. Arora, “Clinical presentation of alcoholic liver disease and non-alcoholic fatty
  16. liver disease: spectrum and diagnosis,” Transl. Gastroenterol. Hepatol., vol. 5, 2020.
  17. M.-J. Xu, Z. Zhou, R. Parker, and B. Gao, “Targeting inflammation for the treatment of alcoholic
  18. liver disease,” Pharmacol. Ther., vol. 180, pp. 77–89, 2017.
  19. J. Xu et al., “Blockade of IL-17 signaling reverses alcohol-induced liver injury and excessive
  20. alcohol drinking in mice. JCI insight. 2020; 5 (3): e131277.” .
  21. S. Yoshiya et al., “Blockade of the apelin–APJ system promotes mouse liver regeneration by
  22. activating Kupffer cells after partial hepatectomy,” J. Gastroenterol., vol. 50, no. 5, pp. 573–582, 2015,
  23. doi: 10.1007/s00535-014-0992-5.
  24. S. A. Phillips, K. Osborn, C.-L. Hwang, A. Sabbahi, and M. R. Piano, “Ethanol induced
  25. oxidative stress in the vasculature: friend or foe,” Curr. Hypertens. Rev., vol. 16, no. 3, pp. 181–191,
  26. M. Ran et al., “Alcohol-induced autophagy via upregulation of PIASy promotes HCV replication
  27. in human hepatoma cells. Cell Death Dis 9: 898.” 2018.
  28. B. Wang et al., “Protective effects of curcumin against chronic alcohol-induced liver injury in
  29. mice through modulating mitochondrial dysfunction and inhibiting endoplasmic reticulum stress,”
  30. Food Nutr. Res., vol. 63, 2019.
  31. X. H. Han, J. Y. Wang, and P. Y. Zheng, “Attenuation and mechanism of endoplasmic reticulum
  32. stress-mediated hepatocyte apoptosis in rats with alcohol-induced liver injury by qinggan huoxue recipe
  33. and its disassembled formulas,” Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi Jiehe Zazhi=
  34. Chinese J. Integr. Tradit. West. Med., vol. 31, no. 5, pp. 653–658, 2011.
  35. J. Fan, “Epidemiology of alcoholic and nonalcoholic fatty liver disease in C hina,” J.
  36. Gastroenterol. Hepatol., vol. 28, pp. 11–17, 2013.
  37. H. A. EDMONDSON, R. L. PETERS, H. H. FRANKEL, and S. BOROWSKY, “The early stage
  38. of liver injury in the alcoholic,” Medicine (Baltimore)., vol. 46, no. 2, pp. 119–129, 1967.
  39. M. Dugum and A. McCullough, “Diagnosis and management of alcoholic liver disease,” J. Clin.
  40. Transl. Hepatol., vol. 3, no. 2, p. 109, 2015.
  41. K. Rasineni and C. A. Casey, “Molecular mechanism of alcoholic fatty liver,” Indian J.
  42. Pharmacol., vol. 44, no. 3, pp. 299–303, 2012.
  43. J. Zhou, Z. Jiang, C. Zhao, Z. Zhen, W. Wang, and A. A. Nanji, “Long‐term binge and escalating
  44. ethanol exposure causes necroinflammation and fibrosis in rat liver,” Alcohol. Clin. Exp. Res., vol. 37,
  45. no. 2, pp. 213–222, 2013.
  46. T. Zeng and K.-Q. Xie, “Ethanol and liver: recent advances in the mechanisms of ethanolinduced hepatosteatosis,” Arch. Toxicol., vol. 83, pp. 1075–1081, 2009.
  47. R. S. O’shea, S. Dasarathy, A. J. McCullough, and P. G. C. of the A. A. for the S. of L. D. and
  48. the P. P. C. of the A. C. of Gastroenterology, “Alcoholic liver disease,” Hepatology, vol. 51, no. 1, pp.
  49. –328, 2010.
  50. P. Puri et al., “Alcohol consumption is associated with the severity and outcome of acute liver
  51. injury/failure,” Liver Int., vol. 40, no. 2, pp. 360–367, 2020.
  52. Y.-H. Yoon and C. M. Chen, “Surveillance Report# 105: Liver cirrhosis mortality in the United
  53. States: National, state, and regional trends, 2000–2013,” Natl. Inst. Alcohol Abus. Alcohol. (NIAAA),
  54. Bethesda, MD, 2016.
  55. K. Shield et al., “National, regional, and global burdens of disease from 2000 to 2016
  56. attributable to alcohol use: a comparative risk assessment study,” Lancet Public Heal., vol. 5, no. 1, pp.
  57. e51–e61, 2020.
  58. C. A. Marroni et al., “Liver transplantation and alcoholic liver disease: History, controversies,
  59. and considerations,” World J. Gastroenterol., vol. 24, no. 26, p. 2785, 2018.
  60. S. Mitra, A. De, and A. Chowdhury, “Epidemiology of non-alcoholic and alcoholic fatty liver
  61. diseases,” Transl. Gastroenterol. Hepatol., vol. 5, 2020.
  62. J. Rehm, A. V Samokhvalov, and K. D. Shield, “Global burden of alcoholic liver diseases,” J.
  63. Hepatol., vol. 59, no. 1, pp. 160–168, 2013.
  64. N. Sheron, “Alcohol and liver disease in Europe–Simple measures have the potential to prevent
  65. tens of thousands of premature deaths,” J. Hepatol., vol. 64, no. 4, pp. 957–967, 2016.
  66. P. S. Mukherjee et al., “Etiology and mode of presentation of chronic liver diseases in India: A
  67. multi centric study,” PLoS One, vol. 12, no. 10, p. e0187033, 2017.
  68. M. D. Glantz et al., “The epidemiology of alcohol use disorders cross-nationally: Findings from
  69. the World Mental Health Surveys,” Addict. Behav., vol. 102, p. 106128, 2020.
  70. H. Li, E. Toth, and N. J. Cherrington, “Alcohol metabolism in the progression of human
  71. nonalcoholic steatohepatitis,” Toxicol. Sci., vol. 164, no. 2, pp. 428–438, 2018.
  72. M. G. Neuman et al., “Alcoholic liver disease: a synopsis of the Charles Lieber’s Memorial
  73. Symposia 2009–2012,” Alcohol Alcohol., vol. 49, no. 4, pp. 373–380, 2014.
  74. S. Zakhari, “Overview: how is alcohol metabolized by the body?,” Alcohol Res. Heal., vol. 29,
  75. no. 4, p. 245, 2006.
  76. C. S. Lieber, “Ethanol metabolism, cirrhosis and alcoholism,” Clin. Chim. acta, vol. 257, no. 1,
  77. pp. 59–84, 1997.
  78. T.-M. Leung and N. Nieto, “CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver
  79. disease,” J. Hepatol., vol. 58, no. 2, pp. 395–398, 2013.
  80. C. Heier, H. Xie, and R. Zimmermann, “Nonoxidative ethanol metabolism in humans—from
  81. biomarkers to bioactive lipids,” IUBMB Life, vol. 68, no. 12, pp. 916–923, 2016.
  82. T. M. Maenhout, M. L. De Buyzere, and J. R. Delanghe, “Non-oxidative ethanol metabolites as a
  83. measure of alcohol intake,” Clin. Chim. Acta, vol. 415, pp. 322–329, 2013.
  84. J. Hyun, J. Han, C. Lee, M. Yoon, and Y. Jung, “Pathophysiological aspects of alcohol
  85. metabolism in the liver,” Int. J. Mol. Sci., vol. 22, no. 11, p. 5717, 2021.
  86. A. Louvet and P. Mathurin, “Alcoholic liver disease: mechanisms of injury and targeted
  87. treatment,” Nat. Rev. Gastroenterol. Hepatol., vol. 12, no. 4, pp. 231–242, 2015.
  88. B. Guo and Z. Li, “Endoplasmic reticulum stress in hepatic steatosis and inflammatory bowel
  89. diseases,” Front. Genet., vol. 5, p. 102163, 2014.
  90. N. A. Osna et al., “Aberrant post-translational protein modifications in the pathogenesis of
  91. alcohol-induced liver injury,” World J. Gastroenterol., vol. 22, no. 27, p. 6192, 2016.
  92. R.-B. Ding et al., “Protective effect of panax notoginseng saponins on acute ethanol-induced
  93. liver injury is associated with ameliorating hepatic lipid accumulation and reducing ethanol-mediated
  94. oxidative stress,” J. Agric. Food Chem., vol. 63, no. 9, pp. 2413–2422, 2015.
  95. S. J. Lee et al., “New potential biomarker proteins for alcoholic liver disease identified by a
  96. comparative proteomics approach,” J. Cell. Biochem., vol. 118, no. 5, pp. 1189–1200, 2017.
  97. R. A. Ansari, K. Husain, and S. A. A. Rizvi, “Role of transcription factors in steatohepatitis and
  98. hypertension after ethanol: the epicenter of metabolism,” Biomolecules, vol. 6, no. 3, p. 29, 2016.
  99. L. Yang et al., “Lipophagy and alcohol-induced fatty liver,” Front. Pharmacol., vol. 10, p. 495,
  100. H.-D. Li et al., “Wogonin attenuates inflammation by activating PPAR-γ in alcoholic liver
  101. disease,” Int. Immunopharmacol., vol. 50, pp. 95–106, 2017.
  102. M. Galicia-Moreno and G. Gutiérrez-Reyes, “The role of oxidative stress in the development of
  103. alcoholic liver disease,” Rev. Gastroenterol. México (English Ed., vol. 79, no. 2, pp. 135–144, 2014.
  104. S. D. Shukla and R. W. Lim, “Epigenetic effects of ethanol on the liver and gastrointestinal
  105. system,” Alcohol Res. Curr. Rev., vol. 35, no. 1, p. 47, 2013.
  106. F. A. R. Lívero and A. Acco, “Molecular basis of alcoholic fatty liver disease: From incidence to
  107. treatment,” Hepatol. Res., vol. 46, no. 1, pp. 111–123, 2016.
  108. T. Jiang, G. Zhang, and Z. Lou, “Role of the sterol regulatory element binding protein pathway
  109. in tumorigenesis,” Front. Oncol., vol. 10, p. 1788, 2020.
  110. X. Cheng, J. Li, and D. Guo, “SCAP/SREBPs are central players in lipid metabolism and novel
  111. metabolic targets in cancer therapy,” Curr. Top. Med. Chem., vol. 18, no. 6, pp. 484–493, 2018.
  112. R. A. DeBose-Boyd and J. Ye, “SREBPs in lipid metabolism, insulin signaling, and beyond,”
  113. Trends Biochem. Sci., vol. 43, no. 5, pp. 358–368, 2018.
  114. H. Shimano, “SREBP-1c and TFE3, energy transcription factors that regulate hepatic insulin
  115. signaling,” J. Mol. Med., vol. 85, pp. 437–444, 2007.
  116. J. T. Nickels, “New links between lipid accumulation and cancer progression,” J. Biol. Chem.,
  117. vol. 293, no. 17, pp. 6635–6636, 2018.
  118. J. Yang and M. S. Stack, “Lipid regulatory proteins as potential therapeutic targets for ovarian
  119. cancer in obese women,” Cancers (Basel)., vol. 12, no. 11, p. 3469, 2020.
  120. K. J. Jeong et al., “Progesterone increases hepatic lipid content and plasma lipid levels through
  121. PR-B-mediated lipogenesis,” Biomed. Pharmacother., vol. 172, p. 116281, 2024.
  122. Q. Long, H. Chen, W. Yang, L. Yang, and L. Zhang, “Delphinidin-3-sambubioside from
  123. Hibiscus sabdariffa. L attenuates hyperlipidemia in high fat diet-induced obese rats and oleic acidinduced steatosis in HepG2 cells,” Bioengineered, vol. 12, no. 1, pp. 3837–3849, 2021.
  124. S. Deng, B. Chen, J. Huo, and X. Liu, “Therapeutic potential of NR4A1 in cancer: Focus on
  125. metabolism,” Front. Oncol., vol. 12, p. 972984, 2022.
  126. Y. Huang, Y. F. Wang, X. Z. Ruan, C. W. Lau, L. Wang, and Y. Huang, “The role of KLF2 in
  127. regulating hepatic lipogenesis and blood cholesterol homeostasis via the SCAP/SREBP pathway,” J.
  128. Lipid Res., vol. 65, no. 1, 2024.
  129. Y. Fan et al., “STAT3 activation of SCAP-SREBP-1 signaling upregulates fatty acid synthesis to
  130. promote tumor growth,” J. Biol. Chem., p. 107351, 2024.
  131. Y. Zhang et al., “Nuclear factor Y participates in alcoholic liver disease by activating SREBP1
  132. expression in mice,” Biochem. Biophys. Res. Commun., vol. 541, pp. 90–94, 2021.
  133. H. K. Seitz et al., “Alcoholic liver disease,” Nat. Rev. Dis. Prim., vol. 4, no. 1, p. 16, 2018.
  134. Thi-Qar Medical Journal (TQMJ): Vol. (28), No. (2), 2024
  135. Web Site: https://jmed.utq.edu Email: utjmed@utq.edu.iq
  136. ISSN (Print):1992-9218 ISSN (Online): 3006-4791
  137. X. Xu, J.-S. So, J.-G. Park, and A.-H. Lee, “Transcriptional control of hepatic lipid metabolism
  138. by SREBP and ChREBP,” in Seminars in liver disease, 2013, vol. 33, no. 04, pp. 301–311.
  139. A. G. Linden et al., “Interplay between ChREBP and SREBP-1c coordinates postprandial
  140. glycolysis and lipogenesis in livers of mice [S],” J. Lipid Res., vol. 59, no. 3, pp. 475–487, 2018.
  141. R.-B. Ding, J. Bao, and C.-X. Deng, “Emerging roles of SIRT1 in fatty liver diseases,” Int. J.
  142. Biol. Sci., vol. 13, no. 7, p. 852, 2017.
  143. J. García-Villafranca, A. Guillén, and J. Castro, “Ethanol consumption impairs regulation of fatty
  144. acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver,” Biochimie,
  145. vol. 90, no. 3, pp. 460–466, 2008.
  146. A. Oliveros-Montiel, G. Santos-López, and V. Sedeño-Monge, “Proteins involved in lipid
  147. metabolism as possible biomarkers or predisposing factors for non-alcoholic fatty liver disease,” Acta
  148. Gastroenterol. Belg., vol. 83, no. 4, pp. 622–630, 2020.
  149. H. Shimano, “SREBPs: physiology and pathophysiology of the SREBP family,” FEBS J., vol.
  150. , no. 3, pp. 616–621, 2009.
  151. J. D. Horton, J. L. Goldstein, and M. S. Brown, “SREBPs: activators of the complete program of
  152. cholesterol and fatty acid synthesis in the liver,” J. Clin. Invest., vol. 109, no. 9, pp. 1125–1131, 2002.
  153. W. Jeong et al., “Paracrine activation of hepatic CB1 receptors by stellate cell-derived
  154. endocannabinoids mediates alcoholic fatty liver,” Cell Metab., vol. 7, no. 3, pp. 227–235, 2008

Most read articles by the same author(s)